Cell-cycle dysregulation and anticancer therapy

Trends in Pharmacological Sciences

Volumn 24, Issue 3, 2003, Pages 139-145

  Stewart, Zoe A ^a   Westfall, Matthew D ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(HYDROXYMETHYL) 1 AZABICYCLO[2.2.2]OCTAN 3 ONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLIN D; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; FR 901228; HISTONE DEACETYLASE INHIBITOR; MS 27275; PROTEIN KINASE; PS 34; SB 2180708; STAUROSPORINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL TRIAL; DNA DAMAGE; DRUG SCREENING; DRUG TARGETING; EUKARYOTIC CELL; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT;

EID: 0037333261     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00026-9     Document Type: Review

References (72)

1. 1-phase progression. Genes Dev. 13:1999;1501-1512.
2. Koepp D.M., et al. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 97:1999;431-434.
3. Zheng L., Lee W.H. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp. Cell Res. 264:2001;2-18.
4. Smits V.A.J., Medema R.H. Checking out the G2/M transition. Biochim Biophys Acta. 1519:2001;1-12.
5. Paulovich A.G., et al. When checkpoints fail. Cell. 88:1997;315-321.
6. Stewart Z.A., Pietenpol J.A. p53 signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14:2001;243-263.
7. Shapiro G.I., et al. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem. Biophys. 33:2000;189-197.
8. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2001;2177-2196.
9. 2 arrest after DNA damage. Science. 282:1998;1497-1501.
10. 2 checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 20:2000;4210-4223.
11. Hermeking H., et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:1997;3-11.
12. Chan T.A., et al. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 401:1999;616-620.
13. 2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2147-2152.
14. Kawabe T., et al. Cdc25C interacts with PCNA at G2/M transition. Oncogene. 21:2002;1717-1726.
15. Musacchio A., Hardwick K.G. The spindle checkpoint: structural insights into dynamic signalling. Nat. Rev. Mol. Cell Biol. 3:2002;731-741.
16. Weinstat-Saslow D.W., et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1995;1257-1260.
17. Wang T.C., et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:1994;669-671.
18. Bortner D.M., Rosenberg M.P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17:1997;453-459.
19. Elsayed Y.A., Sausville E.A. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 6:2001;517-537.
20. Ozbun M.A., Butel J.S. Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv. Cancer Res. 66:1995;71-142.
21. Freedman D.A., et al. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55:1999;96-107.
22. Momand J., et al. The MDM2 gene amplification database. Nucleic Acids Res. 26:1998;3453-3459.
23. kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3:1997;227-230.
24. Porter P.L., et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
25. Muraoka R.S., et al. ErbB2/Neu-induced, cyclin D1-dependent transformation Is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22:2002;2204-2219.
26. Oya M., Schulz W.A. Decreased expression of p57(KIP2) mRNA in human bladder cancer. Br. J. Cancer. 83:2000;626-631.
27. Khanna K.K. Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. 92:2000;795-802.
28. Matsuoka S., et al. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res. 61:2001;5362-5365.
29. Bertoni F., et al. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer. 26:1999;176-180.
30. Bell D.W., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531.
31. Cahill D.P., et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:1998;300-303.
32. Lee H., et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell. 4:1999;1-10.
33. Michel L.S., et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature. 409:2001;355-359.
34. Buolamwini J.K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 6:2000;379-392.
35. Schnier J.B., et al. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. 454:1999;100-104.
36. Oikonomakos N.G., et al. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275:2000;34566-34573.
37. Lam L.T., et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2:2001;. Research0041.
38. Knockaert M., Meijer L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem. Pharmacol. 64:2002;819-825.
39. Knockaert M., et al. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425.
40. cdc2 kinase. Nat. Med. 2:1996;1140-1143.
41. Theron T., et al. The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int. J. Radiat. Biol. 76:2000;1197-1208.
42. Asaad N.A., et al. Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene. 19:2000;5788-5800.
43. Graves P.R., et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275:2000;5600-5605.
44. Jackson J.R., et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 60:2000;566-572.
45. Kwon H., et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother. Oncol. 56:2000;175-179.
46. Mannel R.S., et al. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the gynecologic oncology group. Gynecol. Oncol. 79:2000;64-66.
47. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92:2000;376-387.
48. Liang J., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8:2002;1153-1160.
49. Kip1 at threonine 157 and modulation of its cellular localization. Nat. Med. 8:2002;1145-1152.
50. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:2002;1136-1144.
51. Vivanco I., Sawyers C.L. The phophatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
52. Sato S., et al. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 21:2002;1727-1738.
53. Ling Q., et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 11:2000;2069-2083.
54. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:2002;287-299.
55. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 13:2002;1-13.
56. Nakajima H., et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:1998;126-133.
57. Saito A., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4592-4597.
58. Piekarz R.L., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 98:2001;2865-2868.
59. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin. Oncol. 28:2001;613-619.
60. Weinstein J.N., et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
61. O'Connor P.M., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
62. Amundson S.A., Fornace A.J. Jr., et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60:2000;6101-6110.
63. Scherf U., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244.
64. 2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res. 58:1998;5701-5706.
65. Roberge M., et al. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. Cancer Res. 60:2000;5052-5058.
66. Torrance C.J., et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19:2001;940-945.
67. Bykov V.J., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:2002;282-288.
68. Perego P., et al. Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol. Rev. 52:2000;477-491.
69. Simon J.A., et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60:2000;328-333.
70. Norman T.C., et al. Genetic selection of peptide inhibitors of biological pathways. Science. 285:1999;591-595.
71. Spellman P.T., et al. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevesiae by microarray hybridization. Mol. Biol. Cell. 9:1998;3273-3297.
72. Hughes T.R., et al. Functional discovery via a compendium of expression profiles. Cell. 102:2000;109-126.